A Mathematical Model for Anti-HBV Infection Combination Therapy with Lamivudine and Adevovir Divipoxil

Based on the clinical date of the lamivudine plus adevovir divipolix (combination therapy) for HBeAg-positive chronic hepatitis B patients and the HBV infection dynamic model proposed by Nowak et al., this paper sets up a mathematical model consisting of two differential equation systems that enable us to describe and understand the dynamics of host cells, virus and the immune system. Our model provide a possible interpretation for the effect of combination therapy to the chronic HBV infection patients. In particularly, we can account for the phenomenon of HBV DNA load returned after stopping the therapy. Numerical simulations show that if we proceed with the treatment 8.5 years, the mean HBV DNA levels will decline less than 1 copy/ml.